Observational study of the outcomes and costs of initiating maintenance therapies in patients with moderate exacerbations of COPD

Respiratory Research

Glenn D Crater²  Saurabh P Nagar²  Orsolya E Lunacsek¹  Anna O D’Souza¹  Manan B Shah¹  Anand A Dalal² 

[1] Xcenda, 4114 Woodlands Parkway, Suite 500, Palm Harbor, FL 34685, USA;GlaxoSmithKline, Research Triangle Park, 5 Moore Dr, Bide West, Mail Stop B.3153, Durham, NC 27709, USA

关键词: Fluticasone propionate-salmeterol combination;    Anticholinergics;    Costs;    Moderate COPD exacerbations;    Chronic obstructive pulmonary disease;   

Others  :  796720
DOI  :  10.1186/1465-9921-13-41

 received in 2011-12-13, accepted in 2012-05-10,  发布年份 2012

【 摘 要 】

Background

There are limited data describing patients with moderate COPD exacerbations and evaluating comparative effectiveness of maintenance treatments in this patient population. The study examined COPD patients with moderate COPD exacerbations. COPD-related outcomes were compared between patients initiating fluticasone propionate-salmeterol 250/50 mcg (FSC) vs anticholinergics (ACs) following a moderate COPD exacerbation.

Methods

This retrospective observational study used a large administrative claims database (study period: 2003–2009) to identify and describe patients with an initial, moderate COPD exacerbation. A descriptive analysis of patients with moderate COPD exacerbations was done evaluating maintenance treatment rates, subsequent COPD exacerbation rates, and COPD-related costs during a 1-year period. A cohort analysis compared COPD exacerbation rates and associated costs during a variable-length follow-up period between patients initiating maintenance therapy with FSC or ACs. COPD exacerbations were reported as rate per 100 patient-years, and monthly costs were reported (standardized to USD 2009). COPD exacerbation rates between cohorts were evaluated using Cox proportional hazards models, and costs were analyzed using generalized linear models with log-link and gamma distribution.

Results

21,524 patients with a moderate COPD exacerbation were identified. Only 25% initiated maintenance therapy, and 13% had a subsequent exacerbation. Annual costs averaged $594 per patient. A total of 2,849 treated patients (FSC = 925; AC = 1,924) were eligible for the cohort analysis. The FSC cohort had a significantly lower rate of COPD exacerbations compared to the AC cohort (20.8 vs 32.8; P = 0.04). After adjusting for differences in baseline covariates, the FSC cohort had a 42% significantly lower risk of a COPD exacerbation (HR = 0.58; 95% CI: 0.38, 0.91). The FSC cohort incurred significantly higher adjusted pharmacy costs per patient per month by $37 (95% CI: $19, $72) for COPD-related medications vs the AC cohort. However, this increase was offset by a significant reduction in adjusted monthly medical costs per patient for the FSC vs the AC cohort ($82 vs $112; P < 0.05). Total monthly COPD-related costs, as a result, did not differ between cohorts.

Conclusions

Only a quarter of patients with a moderate COPD exacerbation were subsequently treated with maintenance therapy. Initiation of FSC among those treated was associated with better clinical and economic outcomes compared to AC.

【 授权许可】

   
2012 Dalal et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]GOLD Global Initiative for Chronic Obstructive Lung Disease: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2010. Available from: www.goldcopd.com webcite. Accessed March 1, 2011
• [2]Kochanek KD, Xu J, Murphy SL, Minino AM, Kung HC: Deaths: Preliminary Data for 2009. Natl Vital Stat Rep 2001, 59(4):1-69.
• [3]NHLBI Morbidity and Mortality Chart Book: National Heart. Bethesda: Lung and Blood Institute; 2009.
• [4]Jansson SA, Andersson F, Borg S, Ericsson A, Jönsson E, Lundbäck B: Costs of COPD in Sweden according to disease severity. Chest 2002, 122(6):1994-2002.
• [5]Yu AP, Yang H, Wu EQ, Setyawan J, Mocarski M, Blum S: Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis. J Med Econ 2011, 14(3):315-323.
• [6]Minas M, Hatzoglou C, Karetsi E, Papaioannou AI, Tanou K, Tsaroucha R, Gogou E, Gourgoulianis KI, Kostikas K: COPD prevalence and the differences between newly and previously diagnosed COPD patients in a spirometry program. Prim Care Resp J 2010, 19(4):363-370.
• [7]Kornmann O, Beeh KM, Beier J, Geis UP, Ksoll M, Buhl R: Newly diagnosed chronic obstructive pulmonary disease. Respiration 2003, 70:67-75.
• [8]Fitch K, Iwasaki K, Pyenson B, Plauschinat C, Zhang J: Variation in adherence with Global Initiative for Chronic Obstructive Lung Disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysis. CMRO 2011, 27(7):1425-1429.
• [9]Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT, Yates JC, Willits LR, Vestbo J: Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: Analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009, 10:59. BioMed Central Full Text
• [10]Lee TA, Bartle B, Weiss KB: Spirometry use in clinical practice following diagnosis of COPD. Chest 2006, 129(6):1509-1515.
• [11]Lee TA, Schumock GT, Bartle B, Pickard AS: Mortality risk in chronic obstructive pulmonary disease patients using theophylline. Effective Health Care Research Report No. 16. (Prepared by Chicago-Area DEcIDE Center Under Contract No. HHSA29020050038I TO1). Rockville: Agency for Healthcare Research and Quality; 2009. http://effectivehealthcare.ahrq.gov/reports/final.cfm webcite
• [12]Diette GB, Orr P, McCormack MC, Gandy W, Hamar B: Is pharmacologic care of chronic obstructive pulmonary disease consistent with the guidelines? Popul Health Manag 2010, 12(1):21-26.
• [13]Feifer RA, Aubert R, Verbrugge RR, Khalid M: Disease management opportunities for chronic obstructive pulmonary disease: Gaps between guidelines and current practice. Dis Manag 2002, 5:143-156.
• [14]Rabe KF, Timmer W, Sagkriotis A, Viel K: Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 2008, 134(2):255-262.
• [15]Kurashima K, Hara K, Yoneda K, Kanauchi T, Kagiyama N, Tokunaga D, Takayanagi N, Ubukata M, Sugita Y: Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone. Respirology 2009, 14(2):239-244.
• [16]Bateman ED, van Dyk M, Sagriotis A: Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study. Pulm Pharmacol Ther 2008, 21(1):20-25.
• [17]Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP, UPLIFT investigators: Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009, 374(9696):1171-1178.